Alerts will be sent to your verified email
Verify Email
HEMORGANIC
|
Hemo Organic
|
Zyden Gentec
|
Kobo Biotech
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-361.35 % | -24.76 % | -1.77 % |
|
5yr average Equity Multiplier
|
-1.56 | 2.0 | 4.06 |
|
5yr Average Asset Turnover Ratio
|
0.14 | 0.21 | 0.54 |
|
5yr Avg Net Profit Margin
|
-763.22 % | -137.59 % | -3.79 % |
|
Price to Book
|
0.0 | n/a | 0.0 |
|
P/E
|
40.97 | n/a | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
100.48 Days | 785.76 Days | 0.0 |
|
Inventory Days
|
406.93 Days | 134.34 Days | 89.28 Days |
|
Days Receivable
|
196.55 Days | 803.05 Days | 0.0 |
|
Days Payable
|
2776.86 Days | 421.99 Days | 147.48 Days |
|
5yr Average Interest Coverage Ratio
|
-250.54 | -2.08 | 0.99 |
|
5yr Avg ROCE
|
37.52 % | -6.92 % | 11.79 % |
|
5yr Avg Operating Profit Margin
|
-745.72 % | -95.87 % | 8.83 % |
|
5 yr average Debt to Equity
|
-0.73 | 0.68 | 1.62 |
|
5yr CAGR Net Profit
|
n/a | -1.66 % | n/a |
|
5yr Average Return on Assets
|
-33.34 % | -15.88 % | -0.89 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
16.85 % | 0.0 | 44.95 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -17.28 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Hemo Organic
|
Zyden Gentec
|
Kobo Biotech
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|